Tag: 200-300

On October 7, 1982, Sazonov, N. V.; Grineva, N. A.; Safonova, T. S. published a patent.Safety of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine The title of the patent was Pyrimido[4,5-b][1,4]benzoxazepine derivatives. And the patent contained the following:

I (R = Cl, OH, NH2, benzyl- or phenyl-substituted amino, N-methylpiperazino, R1 = H; R = butyl- or benzyl-substituted amino, morpholino, piperidino, R1 = Br; R = morpholino, R1 = NO2) were prepared by treating aminochloropyrimidines II with hydroxybenzaldehydes III (or alk. salts) in DMF or toluene at 100-20°. The experimental process involved the reaction of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine(cas: 84762-70-9).Safety of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine

The Article related to pyrimidobenzoxazepine amino, benzoxazepine pyrimido, oxazepine pyrimidobenz, Heterocyclic Compounds (More Than One Hetero Atom): Other 7-Membered Rings and other aspects.Safety of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Ibis, Cemil; Ayla, Sibel Sahinler; Ozkok, Funda; Bahar, Hakan published an article in 2015, the title of the article was Synthesis of New Piperazinyl and Piperidinolyl Substituted p-Chloranil Derivatives and their Reactions with Thiols.Safety of 4-(4-Chlorophenyl)piperidin-4-ol And the article contains the following content:

In continuation of previous studies of the nucleophilic substitution reactions of p-chloranil with nucleophiles, novel piperazinyl- and hydroxypiperidinyl-substituted quinones were synthesized. The N-substituted compounds were treated with some thiols and N,S-substituted compounds were obtained. The structures of new products were characterized by spectroscopic methods (1H NMR, 13C NMR, and MS) and elemental anal. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Safety of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to piperazinyl hydroxypiperidinyl chloranil derivative preparation thiol, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Safety of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 25, 2020, Cheng, Zhanling; Khan, Nawaz; Kramer, Christian; Lerner, Christian; Pflieger, Philippe; Stoll, Theodor; Wang, Jianhua; Wang, Yongguang; Yang, Song published a patent.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Novel imidazopyrazine derivatives as antibacterials and their preparation. And the patent contained the following:

The invention provides imidazopyrazine derivatives having formula I, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases. Compounds of formula I wherein ring A is (mono/bi)cyclic C2-9 heterocycloalkyl; R1 is H, amino, C1-6 alkyl-NH, OH, etc.; R2 is H, OH, carbamoyl, etc.; R3 is H, halo, NO2 and CN; R4, R10 and R11 are independently H, halo and C1-6 alkyl; R5, R6, R7, R8 and R9 are independently H, halo, amino, C1-6 alkoxycarbonyl-C1-6 alkoxy, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 2-chloro-4-((3-(2,3-difluoro-4-methoxyphenyl)imidazo[l,2-a]pyrazin-8-yl)amino)benzoic acid with 1-tert-Bu 2-Me piperazine-1,2-dicarboxylate; the resulting 1-tert-Bu 2-Me 4-[2-chloro-4-[[3-(2,3-difluoro-4-methoxy-phenyl)imidazo[1,2-a]pyrazin-8-yl]amino]benzoyl]piperazine-1,2-dicarboxylate underwent Boc-deprotection to give Me 4-[2-chloro-4-[[3-(2,3-difluoro-4-methoxy-phenyl)imidazo[1,2-a]pyrazin-8-yl]amino]benzoyl]piperazine-2-carboxylate, which underwent hydrolysis to give compound II. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited IC90 value of 1.9μM. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to imidazopyrazine preparation antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 25, 2020, Cheng, Zhanling; Khan, Nawaz; Kramer, Christian; Lerner, Christian; Nettekoven, Matthias; Pflieger, Philippe; Puellmann, Bernd; Schmitt, Sebastien; Stoll, Theodor; Wang, Jianhua; Yang, Song published a patent.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Novel imidazopyrazine derivatives as antibacterials and their preparation. And the patent contained the following:

The invention provides imidazopyrazine derivatives having formula I, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases. Compounds of formula I wherein R1 is R12-C1-6 alkyl-X-C1-6 alkyl; R2 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, etc.; R3 is H, halo, C1-6 alkyl, NO2, CN, etc.; R4 and R10 are independently H, halo and C1-6 alkyl; R5, R6, R7, R8 and R9 are independently H, halo, amino, C1-6 alkoxycarbonyl-C1-6 alkoxy, etc.; R11 is H, halo and C1-6 alkyl; R12 is H, vinyl, C2-6 alkynyl, OH, etc.; X is O, NH, S, SO, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II•TFA was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited IC90 value of 0.12μM. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to imidazopyrazine preparation antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 25, 2020, Blanc, Jean-Baptiste; Khan, Nawaz; Kramer, Christian; Lerner, Christian; Pflieger, Philippe; Stoll, Theodor; Yang, Song published a patent.Electric Literature of 1251006-64-0 The title of the patent was Novel imidazopyrazine derivatives as antibacterials and their preparation. And the patent contained the following:

The invention provides imidazopyrazine derivatives having formula I, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases. Compounds of formula I wherein A is C2-9 heterocycloalkyl, C3-12 cycloalkyl, C6-14 aryl and C1-13 heteroaryl; R1 is H, C1-6 alkyl, C1-6 haloalkyl, etc.; R2 is H, OH, carboxyl, amino, etc.; R3, R4 and R5 are independently H and OH; R6 is H, halo, C1-6 alkyl, NO2, CN, etc.; R7 and R13 are independently H, halo and C1-6 alkyl; R8, R9, R10, R11 and R12 are independently H, halo, amino, C1-6 alkoxycarbonyl-C1-6 alkoxy, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 4-((3-(2,3-difluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl)amino)-2-ethylbenzoic acid with tert-Bu cis-N-(3-aminocyclobutyl)carbamate; the resulting 4-((3-(2,3-difluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl)amino)-2-ethylbenzoic acid underwent hydrolysis to give compound II. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited IC90 value of 0.084μM. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Electric Literature of 1251006-64-0

The Article related to imidazopyrazine preparation antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Electric Literature of 1251006-64-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 25, 2020, Blanc, Jean-Baptiste; Cheng, Zhanling; Han, Xingchun; Khan, Nawaz; Kramer, Christian; Kuehne, Holger; Lerner, Christian; Nettekoven, Matthias; Pflieger, Philippe; Puellmann, Bernd; Schmitt, Sebastien; Stoll, Theodor; Wang, Jianhua; Wang, Yongguang; Yang, Song published a patent.Recommanded Product: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Novel imidazopyrazine derivatives as antibacterials and their preparation. And the patent contained the following:

The invention provides imidazopyrazine derivatives having formula I, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases. Compounds of formula I wherein R1 is (un)substituted C1-6 alkyl; R11 is H, halo and C1-6 alkyl; R1R11 can be taken together to form β-, γ-, δ- and ε-lactam; R2 is H, C1-6 alkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, etc.; R3 is H, halo, C1-6 alkyl, NO2, CN, etc.; R4 and R10 are independently H, halo and (un)substituted C1-6 alkyl; R5, R6, R7, R8 and R9 are independently H, halo, amino, C1-6 alkoxycarbonyl-C1-6 alkoxy, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 4-amino-2-methylbenzoic acid with dimethylamine hydrochloride; the resulting 4-amino-N,N,2-trimethylbenzamide underwent arylation with 8-chloro-3-(2,3-difluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazine to give compound II. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited IC90 value of 0.12μM. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Recommanded Product: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to imidazopyrazine antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Recommanded Product: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On June 25, 2020, Cheng, Zhanling; Khan, Nawaz; Kramer, Christian; Lerner, Christian; Pflieger, Philippe; Stoll, Theodor; Wang, Jianhua; Wang, Min; Wang, Yongguang; Yang, Song published a patent.Name: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Novel imidazopyrazine derivatives as antibacterial agents and their preparation. And the patent contained the following:

The invention provides imidazopyrazine derivatives having formula I, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases. Compounds of formula I wherein A is (mono/bi)cyclic C2-9 heterocycloalkyl ring; R1 is H, amino, sulfamoyl, OH, etc.; R2 is H, OH, carbamoyl, etc.; R3 is C1-6 alkyl, C1-6 haloalkyl C2-6 alkenyl, etc.; etc.; R4, R10 and R11 are independently H, halo, and C1-6 alkyl; R5, R6, R7, R8 and R9 are independently H, halo, amino, C1-6 alkoxycarbonyl-C1-6 alkoxy, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 4-((3-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-8-yl)amino)-2-methylbenzoic acid with Me piperidine-4-carboxylate; the resulting Me 1-(4-((3-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-8-yl)amino)-2-methylbenzoyl)piperidine-4-carboxylate underwent hydrolysis to give compound II. The invention compounds were evaluated for their antibacterial activity. From the assay, it was determined that compound II exhibited IC90 value of 1.7μM. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Name: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to imidazopyrazine antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Name: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 7, 2001, Adams, Jerry L.; Boehm, Jeffrey C.; Hall, Ralph F.; Taggart, John J. published a patent.Computed Properties of 357935-97-8 The title of the patent was Preparation of 1,5-disubstituted-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-ones for treatment of CSBP/p38 kinase mediated diseases. And the patent contained the following:

The title compounds (I) [wherein R1 = (un)substituted (hetero)aryl; R2 = H or (un)substituted (cyclo)alkyl(alkyl), (hetero)aryl(alkyl), or heterocyclyl(alkyl); R3 = (un)substituted (cyclo)alkyl(alkyl), (hetero)aryl(alkyl), or heterocyclyl(alkyl); Y = a bond, CRb, CO, NRd, O, or SOm; Rb = H, alkyl, NRc, OH, SH, alkoxy, or SOm-alkyl; Rc and Rd = independently H or alkyl; X = R2, OR2, SOmR2, or (un)substituted (CH2)nNH2; m = 0-2; n = 0-10; or pharmaceutically acceptable salts thereof] were prepared as CSBP/p38 kinase inhibitors. For example, 4,6-dichloro-2-methylsulfanylpyrimidine-5-carbonitrile was condensed with aniline, followed by arylation with PhB(OH)2, reduction of the nitrile using LAH in Et2O, and cyclocondensation of the diamine with COCl2 in toluene and pyridine, to give II. Representative compounds I inhibited CSBP/p38 kinase with IC50 values of < 100 μM. Applications of I to a wide variety of arthritic, inflammatory, proliferative, and viral conditions are specifically claimed. The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Computed Properties of 357935-97-8

The Article related to pyrimidopyrimidinone preparation csbp p38 kinase inhibitor, antiarthritic antiinflammatory immunosuppressant antiviral antitumor pyrimidopyrimidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 357935-97-8

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On July 23, 2020, Looper, Ryan E.; Sebahar, Paul; Reddy, Hariprasada R. Kanna; Haussener, Travis J.; Testa, Charles A.; Tresco, Benlsaac C.; Grant, Seth; Napolitano, Carmela; Sabbatini, Fabio Maria published a patent.Formula: C13H24N2O2 The title of the patent was Preparation of cytosine derivatives as antimicrobial agents. And the patent contained the following:

The invention is directed to compounds I [Z = C(O), C(S), S(O), etc.; ring A = (un)substituted monocyclic heterocycloalkylene or bicyclic heterocycloalkylene; J = absent, (un)substituted alkylene, heterocycloalkylene, etc.; X1 and X2 = (independently) CH or N; Y = (un)substituted linear alkylene, alkenylene, or alkynylene; ring B = (un)substituted monocyclic cycloalkylene or monocyclic heterocycloalkylene; L = absent, or alkylene, wherein up to two methylene units may independently be replaced with O, NH, C(O), etc.; R1 = H, halo, haloalkyl, etc.; R11 = H or (un)substituted NH2; R2 and R3 = (independently) alkyl, halo, CN, etc.; m and n = (independently) 0-3] or pharmaceutically acceptable salts thereof, that are active as antibacterial agents. E.g., a 2-step synthesis of trans-II, starting from tert-Bu (1-(4-((1-(4-formylphenyl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamoyl)piperazin-1-yl)-2-methyl-1-oxopropan-2-yl)carbamate and N-Boc-trans-1,4-cyclohexanediamine, was described. Biol. activity of compounds I was determined (data given). The invention compounds I are active against gram-pos. and gram-neg. bacteria and can be used to treat infections caused by gram-pos. and gram-neg. bacteria. Also disclosed are processes and intermediates for making the compounds I. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Formula: C13H24N2O2

The Article related to cytosine aminopyrimidinone derivative preparation antibacterial antimicrobial, gram pos neg bacteria infection cytosine aminopyrimidinone derivative preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C13H24N2O2

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 22, 2021, Boyle, Robert George; Walker, David Winter; Major, Meriel Ruth published a patent.Computed Properties of 357935-97-8 The title of the patent was Preparation of pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer. And the patent contained the following:

The title compounds I [A = CH or N; R1 = C(OH)(Alk1)(Alk2), N:S(O)(Alk3)(Alk4), or Q; Alk1, Alk2 = same or different C1-3 saturated hydrocarbyl; or Alk1 and Alk2 together with the carbon atom to which they are attached form a C3-4 cycloalkyl ring; Alk3, Alk4 = same or different C1-3 hydrocarbyl; or Alk3 and Alk4 together with the sulfur atom to which they are attached form a 4-6 membered thiacycloalkyl ring; p = 1,2; q = 1,2, provided that the sum of p + q is either 2 or 3; R8 = H, F or Me; R2 = H, halo, C1-3 alkyl C1-3 alkoxy, or C1-3 fluoroalkyl; R3 = H, F, or Me; R4 = H, F, Me, or cyano; R5 = L-Cyc1; L = (CH2)m-B-(CH2)n; m, n = independently 0 or 1; B = absent or C(O)N(Rc), N(Rc)C(O), N(Rc), O, N(Rc)CH2C(O), S, S(O), or S(O)2; Rc = H or C1-4 hydrocarbyl; Cyc1 = each (un)substituted C3-6 cycloalkyl, 4- to 7-membered monocyclic or heterocyclic group containing 1 or 2 heteroatoms selected from N and O, 7- to 11-membered bicyclic heterocyclic group containing 1 or 2 heteroatoms selected from N and O, or phenyl; R6 = H, halo, C1-4 alkyl, C1-4 alkoxy, or C1-4 fluoroalkyl; R7 = C1-4 hydrocarbyl, halo, hydroxy, oxo, C(O)Ra, C(O)ORa, C(O)N(Ra)(Rb), N(Rb)C(O)Ra, N(Rb)C(O)N(Ra)(Rb), or C2-5alkane-diyl, wherein the C2-5alkane-diyl group together with an atom or atoms of Cyc1 to which it is attached forms a cyclic group; Ra, Rb = independently H or C1-3 hydrocarbyl] are prepared The compounds I also including or salts or tautomers thereof are inhibitors of Wee1 kinase and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers. Thus, 2-chloro-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine was coupled with 2-(6-bromo-2-pyridyl)propanol in the presence of CuI, trans-N,N’-dimethylcyclohexane, and K3PO4 in 1,4-dioxane at 100° for 12 h under nitrogen to give 98% 2-[6-(2-chloro-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2-pyridyl]propan-2-ol which was coupled with tert-Bu 4-(4-aminophenyl)piperazine-1-carboxylate in the presence of Li-HMDS in THF at 0° for 30 min and at 100° for 2 h to give 40% tert-Bu 4-[4-[[5-fluoro-7-[6-(1-hydroxy-1-methylethyl)-2-pyridyl]pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate (II; R = Boc). II (R = Boc) was treated with 4 N HCl/1,4-dioxane at room temperature for 2 h to give 70% 2-[6-[5-fluoro-2-[4-(piperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-pyridyl]propan-2-ol dihydrochloride II·2HCl (R = H). II·2HCl (R = H) and 2-[6-[2-[3-chloro-4-(piperazin-1-yl)anilino]-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]-2-pyridyl]propan-2-ol dihydrochloride (III) showed IC50 of 0.010μM, resp., against human Weel kinase. The experimental process involved the reaction of 1-Ethylpiperidin-4-amine dihydrochloride(cas: 357935-97-8).Computed Properties of 357935-97-8

The Article related to pyrrolopyrimidine preparation treatment cancer, wee1 kinase plk1 kinase inhibitor pyrrolopyrimidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 357935-97-8

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem